Literature DB >> 32268210

Identification of prevalent vertebral fractures using Vertebral Fracture Assessment (VFA) in asymptomatic postmenopausal women: A systematic review and meta-analysis.

Jingyan Yang1, Yushan Mao2, Jeri W Nieves3.   

Abstract

BACKGROUND: Vertebral fracture (VF) is the most common osteoporotic fracture in postmenopausal women, although most VFs are subclinical. Prevalent VFs are a significant predictor of subsequent fracture and therefore, identification of VF improves the identification of those with high fracture risk. The aim of present study was to systematically review the literature that assessed the prevalence of VF in asymptomatic postmenopausal women, using Vertebral Fracture Assessment (VFA) by dual-energy X-ray absorptiometry.
METHOD: Medline, Web of Science and Cochrane databases were searched between Jan 1st, 2000 and Jan 31st, 2018, for publications in English that reported the prevalence of VFA-detected VF in asymptomatic postmenopausal women. We also searched for reports, conference papers and grey literature. Reviewers screened studies for eligibility and extracted data for included studies. Random effects meta-analyses were performed to calculate the prevalence of VF. The presence of publication bias was assessed using funnel plots by precision and Egger's Test of the Intercept.
RESULTS: A total of 1777 articles were identified, 94 studies were fully reviewed and 28 studies (n = 25,418) met the inclusion criteria and were analyzed. More than two thirds of the studies were cross-sectional and the sample size varied widely across the studies (from 63 to 5156). The mean age ranged from 59.5 to 86.2 years old. The prevalence of osteoporosis and osteopenia varied between 6-57.0% and 25.1-58.9%, respectively. However, among women who had prevalent VFs, up to 43% had osteopenia and as many as 32% had normal bone density. The weighted pooled prevalence of VFA-detected VF in asymptomatic women was 28% (95% CI: 23%-32%).
CONCLUSION: VFA is able to identify prevalent VF in asymptomatic postmenopausal women. The use of VFA identified an average of 28% of asymptomatic women with VFs, many of whom did not have a diagnosis of osteoporosis. Implementation of VFA as a routine screening tool may detect high risk women. Detection of VF might lead to pharmacological treatment in individuals who may not otherwise be treated.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Osteoporosis; Postmenopausal women; Prevalence; Vertebral Fracture Assessment; Vertebral fracture

Mesh:

Year:  2020        PMID: 32268210     DOI: 10.1016/j.bone.2020.115358

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

1.  The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study.

Authors:  Maria Fusaro; Giovanni Tripepi; Mario Plebani; Cristina Politi; Andrea Aghi; Fulvia Taddei; Enrico Schileo; Martina Zaninotto; Gaetano La Manna; Giuseppe Cianciolo; Maurizio Gallieni; Laura Cosmai; Piergiorgio Messa; Maura Ravera; Thomas L Nickolas; Serge Ferrari; Markus Ketteler; Giorgio Iervasi; Maria Cristina Mereu; Roberto Vettor; Sandro Giannini; Lorenzo Gasperoni; Stefania Sella; Maria Luisa Brandi; Luisella Cianferotti; Raffaele De Caterina
Journal:  Nutrients       Date:  2021-10-12       Impact factor: 5.717

2.  Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX.

Authors:  L Johansson; H Johansson; K F Axelsson; H Litsne; N C Harvey; E Liu; W D Leslie; L Vandenput; E McCloskey; J A Kanis; M Lorentzon
Journal:  Osteoporos Int       Date:  2022-04-22       Impact factor: 5.071

3.  Vertebral Fracture Assessment in Postmenopausal Women With Postsurgical Hypoparathyroidism.

Authors:  Cristiana Cipriani; Salvatore Minisola; John P Bilezikian; Davide Diacinti; Luciano Colangelo; Valentina Piazzolla; Maurizio Angelozzi; Luciano Nieddu; Jessica Pepe; Daniele Diacinti
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.